Abstract
Despite radical surgery, the prognosis for colorectal cancer patients with liver metastases has not changed markedly. Furthermore, no standard adjuvant therapeutic regimen has been developed. Adjuvant therapy with monoclonal antibodies (e.g., against 17-l A), which has been shown to be effective in preventing metastatic relapse in patients with Dukes’ C colorectal cancer, might be a promising approach for these patients. However, the cytotoxic effects of monoclonal antibodies can be blocked by coexpression of complement resistance factors that inhibit antibody-dependent complement-mediated cytotoxicity. We therefore analyzed immunohistochemically the expression of 17-1A and the membrane-bound complement resistance factors CD55 and CDS9 on metastatic tumor cells in the livers of 71 patients with colorectal carcinoma who had undergone resection of their metastases with curative intent. In 67 (94%) of 71 patients, liver metastases with homogeneous expression of 17-IA was seen. Heterogeneous expression of 17-1A was seen in four patients (6%). Heterogeneous expression of CD55 or CD59 was observed in 8 (11%) of 71 patients and 4 (6%) of 71 patients, respectively. None of the patients showed homogeneous expression of either CD55 or CD59. All patients with CD55 or CD59 expression showed homogeneous 17-1A expression, whereas none of the four patients with heterogeneous 17-1A expression was positive for CD55 or CD59. Our data indicate that 17-IA is widely expressed on liver metastases of patients with colorectal carcinoma. Therefore patients with completely resected liver metastases might be suitable candidates for adjuvant therapy with anti-l7-1A antibody since only a few of these lesions showed coexpression of complement resistance factors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Taylor I. Liver metastases from colorectal cancer: Lessons from past and present clinical studies. Br J Surg 1996;83:456–460.
Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Ann Surg 1989;210:127–138.
Sinnige HA, Mulder NH. Colorectal carcinoma: An update. Neth J Med 1991;38:217–228.
Winawer SJ, Zauber AG, Stewart E, O’Brien MJ. The natural history of colorectal cancer. Opportunities for intervention. Cancer 1991;67:1143–1149.
Greenwald P. Colon cancer overview. Cancer 1992;70:1206–1215.
Greenson JK, Isenhart CE, Rice R, et al.. Identification of occult micrometastases in pericolic lymph nodes of Dukes’ B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Cancer 1994;73:563–569.
Liefers GJ, Cleton-Janson AM, Van de Velde CJH, et al.. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223–228.
Izbicki JR, Hosch SB, Pichlmeier U, et al.. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188–1194.
Hosch SB, Knoefel WT, Metz S, et al.. Early lymphatic tumor cell dissemination in pancreatic cancer: Frequency and prognostic significance. Pancreas 1997;15:154–159.
Lindemann F, Schlimok G, Dirschedl P, et al.. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;19:685–691.
Trojani M, de Mascarel I, Bonichon F, et al.. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987;55:303–306.
Passlick B, Izbicki JR, Kubuschok B, et al.. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol 1994;12:1827–1832.
Thorban S, Roder JD, Nekarda H, et al.. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: Detection and prognostic significance. World J Surg 1996;20:567–573.
Laurie JA, Moertel CG, Fleming T, et al.. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of lavamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447–1456.
Moertel CG, Fleming TR, MacDonald JS, et al.. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–358.
Richard S, Farrell CA, Shaw AS, Showell HJ, Connelly PA. CSa as a model for chemotactic factor-stimulated tyrosine phosphorylation in the human neutrophil. J Immunol 1994; 152:2479–2487.
Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruhns D, Kremer B. Frequent expression of complement resistant factors CD46, CD55 and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J Surg Oncol 1997;64:222–230.
Nicholson-Weller A, Wang CE. Structure and function of decay accelerating factor CDSS. J Lab Clin Med 1994;123:485–491.
Morgan BP, Meri S. Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994;15:369–396.
Hughes KS, Simon R, Songhorabodi S, et al.. Resection of the liver for colorectal liver metastases: A multi-institutional study of patterns of recurrence. Surgery 1986;100:278–284.
Sidransky E. Nucleic acid-based methods for detection of cancer. Science 1997;278:1054–1059.
Pantel K, Schlimok G, Braun S, et al.. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419–1424.
Riethmuller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5:732–739.
Dillman RO. The human antimouse response. Antibody Immunocon Radiopharm 1990;3:1–15.
Buchler M, Friess H, Malfertheiner P, et al.. Studies of pancreatic cancer utilizing monoclonal antibodies. Int J Pancreatol 1990;7:151-lS7.
Buchler M, Friess H, Schultheiss KH, et al.. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507–1512.
Sears HE, Mattis J, Herlyn D, et al.. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal turnouts. Lancet 1982;1:762–765.
Sears HE, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985;45:5910–5913.
Mellstedt H, Frodin JE, Masucci G, et al.. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Onco1 1991;2:462–477.
Shaw DR, Kbazaeli MB, Sun KL, et al.. Characterization of a mouse/human chimeric monoclonal antibody (17-IA) to a colon cancer tumor-associated antigen. J Immunol 1987;138:4534–4538.
Herlyn D, Steplewski Z, Herlyn MKH. Colorectal carcinoma specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438–1442.
Cheung N-KV, Walter EI, Smith-Mensah WH, et al.. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest 1988;81:1122–1128.
Riethmiiller G, Schneider-Gädicke E, Schlimok G, et al.. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994;343:1172–1183.
Bosslet K, Keveloh H, Hermentin P, et al.. Percolation and binding of monoclonal antibody BW494 to pancreatic carcinoma tissues during high dose immunology and consequences for future therapy modalities. Br J Cancer 1990; 10:37–39.
Murphy P, Alexander P, Kirkham N, et al.. Pattern of spread of bloodborne tumour. Br J Surg 1986;73:829–836.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Hamburger Krebsgesellschaft and Otto-Stiftung Hamburg, Germany.
Rights and permissions
About this article
Cite this article
Hosch, S.B., Scheunemann, P., Lüth, M. et al. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. J Gastrointest Surg 5, 673–679 (2001). https://doi.org/10.1016/S1091-255X(01)80111-6
Issue Date:
DOI: https://doi.org/10.1016/S1091-255X(01)80111-6